Successful treatment with trisodium phosphonoformate for primary cytomegalovirus infection after heart transplantation
Locke, T.J.; Odom, N.J.; Tapson, J.S.; Freeman, R.; McGregor, C.G.
Journal of Heart Transplantation 6(2): 120-122
1987
ISSN/ISBN: 0887-2570 PMID: 3040944 Document Number: 304640
Primary cytomegalovirus infection in the patient who is receiving immunosuppression therapy is associated with a high morbidity and mortality. We report a patient who developed primary cytomegalovirus infection 37 days after heart transplantation with a rapidly deteriorating course. Treatment with the new antiviral drug trisodium phosphonoformate (Foscarnet-Astra) was initiated as a lifesaving measure with rapid, dramatic improvement in the patient's condition and subsequent recovery.